1.Taha, MK, et al. Serogroup W135 meningococcal disease in Hajj pilgrims. Lancet 2000; 356: 2159.
2.Doganci, L, et al. Neisseria meningitidis W135, Turkey. Emerging Infectious Diseases 2004; 10: 936–937.
3.Fonkoua, MC, et al. Recent increase in meningitis Caused by Neisseria meningitidis serogroups A and W135, Yaounde, Cameroon. Emerging Infectious Diseases 2002; 8: 327–329.
4.Hahne, SJ, et al. W135 meningococcal disease in England and Wales associated with Hajj 2000 and 2001. Lancet 2002; 359: 582–583.
5.Koumare, B, et al. The first large epidemic of meningococcal disease caused by serogroup W135, Burkina Faso, 2002. Vaccine 2007; 25 (Suppl. 1): A37–41.
6.Wilder-Smith, A, et al. Acquisition of W135 meningococcal carriage in Hajj pilgrims and transmission to household contacts: prospective study. British Medical Journal 2002; 325: 365–366.
7.Wilder-Smith, A, et al. Persistence of W135 Neisseria meningitidis carriage in returning Hajj pilgrims: risk for early and late transmission to household contacts. Emerging Infectious Diseases 2003; 9: 123–126.
8.Wilder-Smith, A, et al. Hajj-associated outbreak strain of Neisseria meningitidis serogroup W135: estimates of the attack rate in a defined population and the risk of invasive disease developing in carriers. Clinical Infectious Diseases 2003; 36: 679–683.
9.Wilder-Smith, A, Tai Goh, K. W-135 meningococcal disease in a traveler: a case report. Journal of Travel Medicine 2003; 10: 59–60.
10.Jodar, L, et al. Development of vaccines against meningococcal disease. Lancet 2002; 359: 1499–1508.
11.Ahmed, QA, et al. Health risks at the Hajj. Lancet 2006; 367: 1008–1015.
12.Wilder-Smith, A, et al. Absence of Neisseria meningitidis W-135 electrophoretic Type 37 during the Hajj, 2002. Emerging Infectious Diseases 2003; 9: 734–737.